Cold Spring Harbor Laboratory: Overcoming Resistance in Pancreatic Cancer
September 09, 2019
September 09, 2019
COLD SPRING HARBOR, New York, Sept. 9 -- The Cold Spring Harbor Laboratory issued the following news:
Cancer is relentless and resilient. When a drug blocks a cancer cell's main survival pathway, the cell avoids the obstacle by taking different pathways or detours to save itself. This tactic is called "developing resistance," and it's one of the key challenges researchers face when seeking effective therapeutics to combat pancreatic ductal adenocarcinoma (PDA).
Cancer is relentless and resilient. When a drug blocks a cancer cell's main survival pathway, the cell avoids the obstacle by taking different pathways or detours to save itself. This tactic is called "developing resistance," and it's one of the key challenges researchers face when seeking effective therapeutics to combat pancreatic ductal adenocarcinoma (PDA).